“This year ERT will showcase the widest range of groundbreaking technologies and services that sponsors, bio-tech companies and CROs can leverage to create strategies that vastly improve virtually every aspect of the clinical trial process.
June 9, 2015 (PRWEB) June 09, 2015 -- ERT, a leading global provider of high-quality patient safety and efficacy endpoint data collection, cloud analytics and workflow solutions will embody the theme “Develop, Innovate, Advance” at the 51st Drug Information Association (DIA) Annual Meeting in Washington, DC, June 14-18, 2015. ERT’s scientific, technological and regulatory experts will deliver a series of innovative and educational live demonstrations, presentations and scientific seminars throughout the conference, in its main booth #2025 and via its Innovation Lab Booth #2000.
Advancing eClinical Technology - the ERT Innovation Lab
ERT’s Innovation Lab (Booth 2000) capitalizes on the acceleration and diversification of technological advances for use in new medical product development and broad clinical care. Invited conference attendees can see new concepts ERT is exploring to increase the accuracy and reliability of patient data and improve the efficiency of the clinical development process, including novel integrations of biometric and wearable measurements, wireless ECG data collection integrated into ERT’s electronic Clinical Outcome Assessment (eCOA) Tablet, ERT’s Insights Cloud, ERT’s Respiratory solutions and many other innovative applications ERT is actively pursuing.
James Corrigan, President and CEO of ERT, commented, “This year as never before ERT will showcase the widest range of groundbreaking technologies and services that sponsors, bio-tech companies and CROs can leverage to create strategies that vastly improve virtually every aspect of the clinical trial process.”
ERT's scientific and technological experts will deliver brief live presentations in booth #2025. Attendees can visit with ERT representatives during scheduled breaks and participate in a series of rotating 15 minute presentations, including:
- Town Hall Meeting: How Will ERT’s Acquisition of PHT Impact Me?
- Medication Tracking: Using Technology to Improve Results
- Improving Patient Recruitment and Retention through eCOA
- Improving Data Consistency through Standardized Rater Training
- ERT Insights Cloud: Real-Time Insights Across All Clinical Data Sources
- Wireless ECG / eCOA Tablet Integration
For the full list of presentations, visit http://www.ert.com/dia-annual-meeting.
Featured Scientific Sessions
ERT’s scientific and regulatory experts will deliver sessions and poster presentations on current and practical topics related to patient safety and efficacy data collection:
- 8:00 am: “Remember That? Choosing Recall Intervals for Patient-Reported Outcome Measures,” moderated by Chad Gwaltney, Ph.D., ERT Chief Scientist and Regulatory Advisor, Endpoints
- Poster Presentation: “Lack of Inter-ethnic Difference in QT-susceptibility to moxifloxacin: Two independent TQT studies in Caucasian and Asian Populations,” Yanning Wang, Ph.D., U.S. FDA (research sponsored by ERT)
- Poster Presentation: “The Case for Electronic Data Capture of Abdominal Pain in Crohn’s Disease: A comparison of Diary Methods,” LeighAnn Kelly-Lichter, Ph.D., ERT Scientist
- Poster Presentation: “Measurement Equivalence of the SF-36v2 on a Handheld Device and Smartphone App,” Susan M. Dallabrida, Ph.D., ERT Vice President of Clinical Science and Consulting
- 10:30 am: “The Effect of the Number of ECG Replicates per Timepoint on QTc within Subject Variability in a QT study,” presented by Robert Kleiman, M.D., ERT Chief Medical Officer and Vice President, Global Cardiology
- 9:00 am: “Bring Your Own Device (BYOD) Approaches to the Collection of Electronic Patient-Reported Outcome Data in Clinical Trials,” moderated by Dr. Chad Gwaltney
- Poster Presentation: “Review of Adherence Measures for Use in Phase IV Studies and Recommendations for a New Standardized Generic Measure,” Colleen McHorney, Ph.D., ERT Senior Scientist
For additional information on ERT’s DIA presentations, Innovation Lab, and other activities visit http://www.ert.com/dia-annual-meeting.
ERT (http://www.ert.com) is a leading provider of high-quality patient safety and efficacy endpoint data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services and consulting that increase the accuracy and reliability of patient data and improve the efficiency of the clinical development process throughout the product lifecycle. ERT delivers the most widely deployed solutions in centralized Cardiac Safety, Respiratory, Suicide Risk Assessment, electronic Clinical Outcome Assessments (eCOA) – which includes patient-, clinician-, observer- and performance-reported outcomes and cloud based analytics and performance metrics. By efficiently integrating these solutions through a system built upon a scientific and regulatory foundation, ERT collects, analyzes and delivers safety and efficacy data critical to the approval, labeling and reimbursement of pharmaceutical products. ERT is a global organization with headquarters in Philadelphia, PA and offices throughout the U.S., U.K., Switzerland, Japan and Germany.